The DOI matches its Crossref record; 439 of the 439 references it cites were found in a registry or an index.
Japanese Clinical Practice Guideline for Diabetes 2019
Open accessAbstract
The current guideline represents the 6th edition of the 'Japanese Clinical Practice Guideline for Diabetes' which has been revised every three years since its first appearance in 2004 to promote evidence-based, rational, efficient and consistent clinical practice in diabetes. Of note, dramatic progress has been made in recent years in diabetes research and clinical practice, which includes approval of antidiabetic agents with novel mechanisms of action along with publication of clinical trial results with these drugs, and novel diagnostic and therapeutic devices, such as continuous glucose monitoring (CGM) and sensor augmented pumps (SAP). Again, results from large-scale clinical trials in Japan, such as J-DOIT 1 to 3 and JDCP studies, have recently been reported. Further, in the last three years, new guidelines for lipid and blood pressure control have been released in a timely fashion from the Japan Atherosclerosis Society and the Japanese Society of Hypertension. Therefore, the current guideline has been compiled to include not only relevant advances in clinical practice but novel findings and new lines of evidence that have been made available to date. While the current guideline has been organized along similar lines to those of the preceding 2016 edition and using the same clinical questions (CQs) and questions (Qs) format, each CQ or Q has been closely reviewed for revision and further CQs or Qs have been added as appropriate to further promote the use of the guidelines in clinical practice. Readers are therefore referred to the 'Methods of developing the "Japanese Clinical Practice Guideline for Diabetes 2019"' for a detailed account of the guideline development processes involved to make effective use of the current guideline. It is hoped that the guideline will prove a helpful guide to evidence-based medicine (EBM) in clinical settings thereby contributing not only to prolongation of healthy lifespan but to improved quality of life in patients with diabetes. The guideline consists of general questions (cited as Qs) and clinical questions (cited as CQs) followed by explanations. Statements of recommendation were developed solely for CQs. Clinical guideline committee (CGC) members conducted systematic review (SR) of evidence from several resources to develop a statement of recommendation for CQs and presented a strength of recommendation rated as a grade. SR support team helped CGC members to make literature retrieval and confirm an evidence level for articles that they obtained. A brief criterion of the literature retrieval process was shown in this guideline. We referred to all the important articles necessary for the judgement of a statement and its strength of recommendation for CQs. Abstract tables were constructed solely for the articles necessary to recommend a statement for CQs. They contained relevant articles with PICO (Populations, Interventions, Comparators, Outcomes of interest), study design, and evidence level as defined in Table 1. The quality of evidence was also summarized based on 5 items for meta-analysis or systematic review, and 3 items for randomized controlled trial as shown in Table 1. The grade of recommendation was determined by each CGC member with consideration given to certainty of overall evidence, balance of benefits and harms, patient preferences/values, and costs (Table 2). Grades A and B stand for strong and weak recommendations, respectively. The CGC members reviewed and discussed all CQ guidelines. Votes were taken for each recommendation statement. A 75% agreement among eligible CGC members was required to approve each recommendation and its strength. Satisfies all of the following 5 items: Satisfies all of the following 3 items: I. Type 1 (Characterized by pancreatic β-cell destruction usually leading to absolute insulin deficiency) III. Diabetes due to some other specific mechanism or disease Individuals who have met the above criteria 1–3 are to be diagnosed with acute-onset (autoimmune) type 1 diabetes. Those who have met the above criteria 1, 2, and 4 are to be diagnosed with acute-onset type 1 diabetes. Those who have met the above criteria 1 and 2 but not 3 and 4 are to be re-evaluated after an interval with the diagnosis put on hold. Those who have met the criteria for fulminant type 1 diabetes are to be diagnosed as such. Some may lead to the onset of ketosis or ketoacidosis within about 1–2 weeks. The onset of fulminant type 1 diabetes may be associated with pregnancy. Exocrine pancreatic enzymes, e.g., amylase, lipase, and esterase 1, are shown to be elevated in 98% of affected individuals. Upper airway and gastrointestinal symptoms are noted in 70% of affected individuals. Fulminant type 1 diabetes is shown to be linked to HLA DRB1*04:05–DQB1*04:01. [Q2-3] How is the glycemic goal to be set for each individual patient? (Figure 5) Glucose levels in affected individuals are to be controlled as close to normal as possible. Achieving and maintaining favo
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–439 of 439
Derosa, G., SALVADEO, S. A. T., D’Angelo, A., Ferrari, I., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., & Cicero, A. F. G. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802711024 · Cited by 43
Simpson, S. H., Gamble, J., Mereu, L., & Chambers, T. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1757-y · Cited by 42
Ahmadi-Abhari, S., Luben, R. N., Powell, N., Bhaniani, A., Chowdhury, R., Wareham, N. J., Forouhi, N. G., & Khaw, K.-T. (2014) · British Journal of Nutrition · doi:10.1017/s0007114513002298 · Cited by 42
Zhang, Q., Dou, J., & Lu, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.06.006 · Cited by 41
Yui, Y., Sumiyoshi, T., Kodama, K., Hirayama, A., Nonogi, H., Kanmatsuse, K., Origasa, H., Iimura, O., Ishii, M., Saruta, T., et al. (2004) · Hypertension Research · doi:10.1291/hypres.27.449 · Cited by 40
Self-citationScheen, A. J., Tan, M. H., Betteridge, D. J., Birkeland, K. I., Schmitz, O., Charbonnel, B. H., & on behalf of the PROactive investigators (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02816.x · Cited by 39
Takahashi, K., Nishimura, F., Kurihara, M., Iwamoto, Y., Takashiba, S., Miyata, T., & Murayama, Y. (2001) · PubMed · Cited by 37
for the CASE-J Trial Group, Nakao, K., Hirata, M., Oba, K., Yasuno, S., Ueshima, K., Fujimoto, A., Ogihara, T., & Saruta, T. (2010) · Hypertension Research · doi:10.1038/hr.2010.38 · Cited by 37
Report of the JDS/JCA Joint Committee on Diabetes and Cancer
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0121-3 · Cited by 37
Self-citationNauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Kähler, P., Grevstad, B., Almdal, T., Gluud, C. N., Wetterslev, J., Vaag, A. A., & Hemmingsen, B. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004806 · Cited by 35
Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes
Ceysens, G., Brown, J., & Boulvain, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012202 · Cited by 35
Satoh, J., Yagihashi, S., Baba, M., Suzuki, M., Arakawa, A., & Yoshiyama, T. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00122.x · Cited by 34
Sick day management in children and adolescents with diabetes: ISPAD Sick Day Guidelines 2014
Brink, S. J., Joel, D. R., Laffel, L. M., Lee, W. W. R., Olsen, B. S., Phelan, H., & Hanås, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12193 · Cited by 31
Siersma, V., Thorsen, H., Holstein, P., Kars, M., Apelqvist, J., Jude, E. B., Piaggesi, A., Bakker, K., EDMONDS, M. E., Jirkovská, A., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.008 · Cited by 30
Imagawa, A., Hanafusa, T., Awata, T., Ikegami, H., Uchigata, Y., Osawa, H., Kawasaki, E., Kawabata, Y., Kobayashi, T., Shimada, A., et al. (2012) · Diabetology International · doi:10.1007/s13340-012-0098-3 · Cited by 29
Self-citationGoto, A., Noto, H., Noda, M., Ueki, K., Kasuga, M., Tajima, N., Ohashi, K., Sakai, R., Tsugane, S., Hamajima, N., et al. (2016) · Diabetology International · doi:10.1007/s13340-016-0257-z · Cited by 29
Self-citationde Luis, D. A., Aller, R., Cuéllar, L., et al. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1844 · Cited by 28
Screening and treatment of childhood type 1 and type 2 diabetes mellitus in Japan.
Urakami, T., Suzuki, J., Mugishima, H., et al. (2012) · PubMed · Cited by 27
Lee, W., Yoon, Y., Han, H., Cho, J. Y., Choi, Y., Jang, J. Y., & Choi, H. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24133 · Cited by 27
Haneda, M., Kikkawa, R., Sakai, H., & Kawamori, R. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.02.015 · Cited by 26
Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus
Feinglos, M. N., Thacker, C. R., Lobaugh, B., DeAtkine, D., McNeill, D., English, J. S., & Bursey, D. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00003-5 · Cited by 25
Terauchi, Y., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13213 · Cited by 25
Tanaka, S. A., Ohmori, M., Awata, T., et al. (2015) · Diabetology International · doi:10.1007/s13340-015-0210-6 · Cited by 24
Kadowaki, T., Tajima, N., Odawara, M., Minamide, T., Kawashima, M., Yanagida, D., Okamoto, T., & Ferreira, J. C. A. (2013) · Diabetology International · doi:10.1007/s13340-013-0109-z · Cited by 24
Allemann, S., Diem, P., Egger, M., Christ, E., & Stettler, C. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89865 · Cited by 24
Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes.
Juntti‐Berggren, L., Pigon, J., Hellström, P. M., Holst, J. J., & Efendić, S. (2000) · PubMed · Cited by 20
Kawasaki, E., Maruyama, T., Imagawa, A., Awata, T., Ikegami, H., Uchigata, Y., Osawa, H., Kawabata, Y., Kobayashi, T., Shimada, A., et al. (2013) · Diabetology International · doi:10.1007/s13340-013-0122-2 · Cited by 19
Self-citationComparative risk of new‐onset diabetes mellitus for antihypertensive drugs: A network meta‐analysis
Li, Z., Li, Y., Liu, Y., Xu, W., & Wang, Q. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13108 · Cited by 17
Yamashita, K., Kondo, T., Muramatsu, T., Matsushita, K., Nagahiro, T., Maeda, K., Shintani, S., & Murohara, T. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.07.043 · Cited by 15
Self-citationYamada, S., Watanabe, M., Funae, O., Atsumi, Y., Suzuki, R., Yajima, K., Nakamura, Y., Kawai, T., Oikawa, Y., & Shimada, A. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.0415 · Cited by 14
Kaku, K., Sumino, S., Katou, M., Nishiyama, Y., & Kinugawa, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12837 · Cited by 13
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2016) · Journal of General and Family Medicine · doi:10.14442/jgfm.17.1_60 · Cited by 12
Self-citationÖzbek, M., Erdogan, M., Karadeniz, M., et al. (2006) · Acta Diabetologica · doi:10.1007/s00592-006-0231-5 · Cited by 12
Kaku, K., Tajima, N., & Kawamori, R. (2006) · 糖尿病 · Cited by 10
Kaku, K., Inagaki, N., & Kobayashi, N. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0051-5 · Cited by 8
Aoki, C., Suzuki, K., Kuroda, H., Sagara, M., Shimizu, M., Kasai, K., & Aso, Y. (2017) · PubMed · doi:10.18999/nagjms.79.1.9 · Cited by 8
Ono, Y., Nakamura, A., Cho, K. Y., & Nomoto, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.868437 · Cited by 6
Clinical Features of Eighty-six Diabetic Patients with Post-treatment Painful Neuropathy.
Takahashi, Y., Takayama, S., Ito, T., et al. (1998) · Tōnyōbyō/Tounyoubyou · Cited by 6
Cited by
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Inagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Kadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00187-5 · Cited by 131
Metadata
- Authors
- Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., & Yoshioka, N.
- Venue
- Journal of Diabetes Investigation
- Publisher
- Wiley
- Published
- 2020-07
- Volume
- 11
- Issue
- 4
- Pages
- 1020-1076
- ISSN
- 2040-1116 (ISSN-L)
- 2040-1124
- OpenAlex
- W4211009683
- Cited by
- 341
- References
- 439
- FWCI
- 29.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.